Age of respondents (years) | Year of diagnosis | ||
<20 | 0.85% | 2013 | 15.4% |
21–30 | 4.5% | 2014 | 14.8% |
31–40 | 14.83% | 2015 | 18.9% |
41–50 | 31.55% | 2016 | 24.1% |
51–60 | 32.01% | 2017 | 23.2% |
61–70 | 14.24% | 2018 | 3.6% |
71–80 | 1.83% | ||
>80 | 0 | ||
Ovarian cancer stage on diagnosis | Status at time of survey | ||
Stage I | 29.0% | Receiving first-line treatment | 10.7% |
Stage II | 11.5% | In remission | 55% |
Stage III | 43.8% | ||
Stage IV | 12.8% | ||
I do not know/cannot remember | 2.9% | ||
Most common types of ovarian cancer | Average for all respondents | Significant variations | p Values (corr to 3dp) and z scores |
Epithelial serous ovarian cancer | 34% | Hungary 17.2% Canada 44.3% | p=0.001, z=−3.29 p=0.011, z=2.55 |
Epithelial endometrioid ovarian cancer | 10% | Germany 2.8% UK 5.7% Japan 21.6% | p=0.000, z=−4.49 p=0.002, z=−2.26 p=0.000, z=4.28 |
Epithelial clear cell ovarian cancer | 9.4% | Brazil 1.9% Germany 3.6% Japan 22% | p=0.038, z=−3.66 p=0.001, z=−3.39 p=0.000, z=4.62 |
I don’t know/cannot remember | 12.5% | Brazil 3.9% Japan 4% Italy 5.4% Germany 22% Hungary 29.3% | p=0.002, z=−3.11 p=0.000, z=−5.69 p=0.005, z=−2.83 p=0.000, z=2.63 p=0.000, z=2.78 |